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Abstract
Cardiovascular disease (CVD) is the main public health problem in patients with chronic kidney disease (CKD); however, there is no
established biomarker for predicting CVD morbidity and mortality in CKD. The aim of this study was to evaluate the role of circulating
tumor necrosis factor receptors (cTNFRs) in predicting CVD risk in CKD patients.
Weprospectively recruited 984 patientswith CKD from11 centers between 2006 and 2012. The levels of cTNFR1 andcTNFR2were
determined by performing an enzyme-linked immunosorbent assay. During the mean follow-up period of 4 years, 36 patients
experienced a CVD event. The median serum concentrations of cTNFR1 and cTNFR2 were 2703.4 (225.6–13,057.7) and 5661.0
(634.9–30,599.6)pg/mL, respectively, and the cTNFR1 level was closely correlated with the cTNFR2 level (r=0.86, P< .0001). The
urinary protein-to-creatinine ratio (UPCR) and estimated glomerular ﬁltration rate (eGFR) were signiﬁcantly correlated with the cTNFR2
level (r=0.21 for UPCR, r=0.67 for eGFR; P< .001 for all). Similar correlations were observed for serum cTNFR1 (r=0.21 for UPCR,
r=0.75 for eGFR;P< .001 for all). In theCoxproportional hazard analyses, cTNFR1 (hazard ratio [HR] 2.506, 95%conﬁdence interval
[CI] 1.186–5.295,P= .016) andcTNFR2 (HR4.156, 95%CI 1.913–9.030,P< .001) predictedCVD risk even after adjustment for clinical
covariates, such asUPCR, eGFR, and high-sensitivity C-reactive protein. cTNFR1 and 2 are associatedwith CVD and other risk factors
in CKD, independently of eGFR and UPCR. Furthermore, cTNFRs could be relevant predictors of CVD in CKD patients.
Abbreviations: BMI = body mass index, CKD = chronic kidney disease, CVD = cardiovascular disease, DM = diabetes mellitus,
ESRD= end-stage renal disease, GFR= glomerular ﬁltration rate, HF= heart failure, HTN = hypertension, MI =myocardial infarction,
NRI = net reclassiﬁcation improvement, TNF-a = tumor necrosis factor-a, TNFR = tumor necrosis factor receptor, UPCR = urinary
protein-to-creatinine ratio.
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Chronic kidney disease (CKD) affects 10% to 16% of the adult
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1increasing. In accordance with increasing prevalence of
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Therefore, CVD is one of the main public health problems
affecting these patients; however, traditional risk factors, such as
old age, hypertension (HTN), and dyslipidemia, cannot sufﬁ-
ciently explain its high incidence.
Recurrent or chronic inﬂammatory processes are common in
individuals with CKD.[7] A role of inﬂammation has become well
established in theories describing the atherosclerotic disease
process, and inﬂammation is common in heart disease and stroke
patients.[8]
Tumor necrosis factor-a (TNF-a) is a pleiotropic cytokine that
plays an essential role in mediating inﬂammatory processes.[9–11]
It binds to 2 distinct TNF receptors (TNFRs), TNFR1 and
TNFR2, which are the key mediators of TNF signaling.[8] The
plasma levels of circulating TNFRs (cTNFRs) are signiﬁcantly
increased in CKD patients, and these levels are closely correlated
with kidney function.[12] These biomarkers are also predictive of
declining kidney function.[13–16] Further, we have recently
reported that cTNFRs may be biomarkers for CKD progression
in patients with glomerular nephritis, such as IgA nephropathy
and membranous nephropathy, as well as in patients undergoing
invasive coronary angiography.[17–19] There has been particular
interest in searching for biomarkers that may be predictive of
CVD morbidity and mortality in the CKD population. To date,
cystatin C,[20,21] uric acid,[22] natriuretic peptides,[23] plasma
renin activity,[24] and ﬁbroblast growth factor-23[25] have been
investigated as biomarkers for predicting CVD in CKD patients.
However, data on the association between TNFRs and CVD in
these patients are scarce. Therefore, we aimed to explore the role
of serum TNFRs in the occurrence of CVD in CKD patients.2. Methods
2.1. Study population and data collection
A total of 984 CKD patients were prospectively enrolled from 11
centers in South Korea between 2006 and 2012 (Fig. 1). This
study was reviewed and approved by the Institutional Review
Board of each center. We conducted the study according to the
principles of the Declaration of Helsinki and obtained written
informed consent from all of the participants.
The inclusion criteria were as follows: adult patients (aged ≥19
years), and CKD stage from 1 to 5 (predialysis) based on the
estimated glomerular ﬁltration rate (eGFR). Excluded subjects
were those who were unable or unwilling to provide written
consent, had previously received chronic dialysis or organ
transplantation, had heart failure (HF; New York Hear
Association class 3 or 4) or liver cirrhosis (Child-Pugh class 21,175 patients screened
from 2006 to 2012
Excluded (n=101)
- <18 years of age (n=15)
- Previously received chronic dialysis or 
organ transplantation (n=26)
- Heart failure, NYHA class 3 or 4 or liver 
cirrhosis (n=17)
- History of cardiovascular disease (n=23)
- Denied to participate (n=20)
1,074 patients with CKD
Excluded 90 patients with unavailable 
samples
984 patients
Figure 1. Flow diagram of patient enrollment.
2or 3), or had history of CVD, or were currently pregnant, or had
unavailable samples to analysis cTNFR level.
Demographic and laboratory data were recorded at the time of
enrollment. Follow-up visits occurred every 6months, and during
each visit, the subjects were evaluated to determine whether they
had experienced cardiovascular events or received renal replace-
ment therapy.
The serum creatinine (sCr) levelwasmeasured by an assay based
on isotope dilution mass spectrometry (IDMS), and the eGFRwas
calculated using the following IDMS-traceable Modiﬁcation of
Diet in Renal Disease equation: GFR (mL/min/1.73m2)=175
(sCr) (1.154) (age in years)(0.203) (0.742, if female). CKD was
deﬁned as the presence of kidney damage or decreased kidney
function for 3 months or more months. The kidney damage
includes albuminuria above albumin-to-creatinine ratio>30mg/g
or urine sediment abnormalities or pathologic abnormalities or
structural abnormalities detected by imaging.[6] HTNwas deﬁned
as a systolic blood pressure (SBP) ≥140mm Hg, diastolic blood
pressure ≥ 90mm Hg, or the use of antihypertensive medication.
Diabetesmellitus (DM)was deﬁned as a fasting glucose level≥126
mg/dL, hemoglobin A1c≥6.5%, the use of a glucose-lowering
drug, or self-reported diabetes.2.2. Clinical assessment
The primary endpoint was deﬁned as the ﬁrst occurrence of either
cardiovascular death, nonfatal myocardial infarction (MI),
revascularization, or fatal/nonfatal stroke. Cardiovascular death
included fatal MI, sudden death, death caused by congestive HF,
death attributable to a diagnostic or therapeutic procedure due to
coronary artery disease, and death from another coronary
cause.[26] The secondary endpoints were deﬁned as all-cause
mortality (cardiovascular and noncardiovascular) and end-stage
renal disease (ESRD) (with receipt of renal replacement therapy,
such as peritoneal dialysis, hemodialysis or kidney transplanta-
tion).[26] The date and cause of death were reported within 1
month after the event. For the patients who withdrew from the
study, we ascertained mortality data from Statistics Korea.[27]
2.3. Blood sample collection and measurement of TNFRs
Peripheral blood was withdrawn from venous blood vessels and
collected in ethylenediamine tetraacetic acid containing tubes. Blood
specimenswere immediately cooled and centrifuged at 3000rpm for
10min, and serum samples were stored at 70 °C until tested. The
cTNFR1 and cTNFR2 levels were determined using enzyme-linked
immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN)
according to the manufacturer’s Instructions. The following
quantikine ELISA kits were used: human sTNFRI (catalog number
DRT100)/human sTNFRII Quantikine ELISA Kit (catalog number
DRT200). The samples were subjected to duplicate and blind
testing. Absorbancewasmeasuredwith an ELISA reader at 450nm.
The minimum detectable concentration was 0.43 to 1.20pg/mL for
sTNFR1and 0.2 to 2.3pg/mL for sTNFR2.
2.4. Statistical analysis
The data are presented as the mean± standard deviation or the
frequency (count and percentage). The cTNFR levels that were
not normally distributed are expressed as the median and
interquartile range (IQR) or are presented as log-transformed
values. The subjects’ characteristics were analyzed using Student t
test for continuous variables, the chi-square test for categorical
variables, or one-way analysis of variance using Scheffe multiple
Table 1
Baseline characteristics.
Characteristic
Age, y
∗
49.7±15.8
Sex, male (n, %) 552 (56.1%)
hs-CRP, mg/dL
∗
0.7±2.4
cTNFR1, pg/mL† 2703.4 (225.6–13,057.7)
cTNFR2, pg/mL† 5661.0 (634.9–30,599.6)
eGFR, mL/min/1.73m2
∗
50.8±31.6
eGFR categories
>90 139 (14.4%)
60–90 178 (18.4%)
30–60 301 (31.1%)
15–30 330 (34.1%)
<15 19 (2.0%)
UPCR, g/g cr
∗
2.2±2.6
Albumin, g/dL
∗
3.9±0.6
LDL cholesterol, mg/dL
∗
95.8±58.1
BMI, kg/m2
∗
24.0±3.7
SBP, mm Hg
∗
128.2±16.8
Hypertension (n, %) 527 (53.6%)
Diabetes (n, %) 267 (27.1%)
BMI = body mass index, eGFR = estimated glomerular ﬁltration rate, LDL = low-density lipoprotein,
SBP = systolic blood pressure, UPCR = urine protein-to-creatinine ratio.
∗
Data are expressed as the mean± standard deviation or the median (25th and 75th percentiles).
† Data are expressed as the median and interquartile range (IQR).
Table 2
Clinical parameters according to circulating tumor necrosis factor
receptor s and circulating tumor necrosis factor receptor 2
concentrations.
Ln cTNFR1 T1 Ln cTNFR1 T2 Ln cTNFR1 T3 P
Range, pg/mL <7.226 7.226–8.115 ≥8.116
n 329 328 327
Age, y 40.1±14.7 53.2±14.0 55.9±13.9 <.001
Sex, male (n, %) 142 (43.2) 198 (60.4) 212 (64.8) <.001
hs-CRP, mg/dL
∗
0.6±1.6 0.5±1.1 0.9±3.4 .059
eGFR, mL/min/1.73m2
∗
80.9±27.0 46.1±24.7 25.7±10.2 <.001
UPCR, g/g cr
∗
1.6±2.3 2.3±2.9 2.7±2.6 <.001
Albumin, g/dL
∗
4.0±0.6 3.8±0.7 3.8±0.6 <.001
LDL cholesterol, mg/dL
∗
86.0±66.6 105.2±62.5 97.1±41.6 .001
BMI, kg/m2
∗
23.1±3.4 24.4±3.7 24.3±3.8 <.001
SBP, mm Hg
∗
125.0±15.1 128.7±17.3 131.1±17.3 <.001
Hypertension (n, %) 218 (66.3) 183 (55.8) 126 (38.5) <.001
Diabetes (n, %) 21 (6.4) 92 (28.0) 154 (47.1) <.001
Ln cTNFR2 T1 Ln cTNFR2 T2 Ln cTNFR2 T3 P
Range, pg/mL <8.068 8.068–8.811 ≥8.811
n 326 326 328
Age, y
∗
40.8±15.1 51.4±13.7 56.8±14.0 <.001
Sex, male (n, %) 147 (44.7) 202 (61.8) 203 (61.9) <.001
hs-CRP, mg/dL
∗
0.6±1.6 0.4±1.1 1.0±3.4 .013
eGFR, mL/min/1.73m2
∗
76.6±28.4 47.3±27.4 28.6±15.6 <.001
UPCR (g/g creatinine)
∗
1.5±2.1 2.3±2.9 2.8±2.7 <.001
Albumin, g/dL
∗
4.0±0.6 3.8±0.7 3.8±0.6 <.001
LDL cholesterol, mg/dL
∗
88.1±64.3 101.4±63.0 98.0±44.5 .024
BMI, kg/m2
∗
23.2±3.4 24.3±3.5 24.4±3.9 <.001
SBP, mm Hg
∗
126.2±16.4 128.0±16.8 130.5±17.0 .004
Hypertension, (n, %) 234 (71.1) 156 (47.7) 137 (41.8) <.001
Diabetes (n, %) 25 (7.6) 85 (26.0) 157 (47.9) <.001
BMI = body mass index, CVD = cardiovascular disease, eGFR = estimated glomerular ﬁltration rate,
LDL= low-density lipoprotein, SBP = systolic blood pressure, UPCR = urine protein-to-creatinine ratio.
∗
Data are expressed as the mean± standard deviation or the median (25th and 75th percentiles). The
chi-squared test and analysis of variance was used.
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analysis was performed to analyze the correlations between the
log-transformed cTNFR (ln cTNFR) levels and variables. To
identifyCVDevents according to the cTNFR levels, Kaplan–Meier
analyses and log-rank tests were performed. Furthermore,
multivariate Cox proportional hazards regression analysis using
the forward stepwise process was applied to identify associations
between the cTNFR levels and CVD events. Analyses were
performed using SPSS version 21.0 software (IBM Corporation,
Armonk, NY), and statistical signiﬁcance was deﬁned as P< .05.
To identify the level of statistical power, we computed post hoc
power analysis using Gpower version 3.1 software (Franz,
UniversitatKiel,Germany) andXLSTATversion2016.3 (Addinsoft,
New York, NY) software for the Cox proportional hazard model
because this is end of the study.[28,29] The statistical power in this
study was at least 98% for a given sample size (n=984), effect size
(0.02, using the estimates from this study), and alpha level (0.05). All
elementsused in thecalculationare conservativevalue suchas sample
size and effect size with small convention value.
To evaluate the model performance according to the contribu-
tions of cTNFRs to the prediction of CVD events, c statistics was
calculated using the area under the receiver-operating curve. For
the statistical signiﬁcance and 95% conﬁdence intervals (CIs) for c
statistics, Mann–Whitney contrast test was used. In addition, the
continuousnet reclassiﬁcation improvement (cNRI)wascomputed
using logistic regression models with the function improveprob in
R. The NRI quantiﬁes the increase in predicted risk categories for
events and the decrease in risk categories for nonevents with the
addition of a new marker.[30,31] Data were analyzed by using SAS
9.4 for Windows software (SAS Institute, Cary, NC) and R
software version3.2.3 (ComprehensiveRArchiveNetwork: http://
cran.r-project.org). In all analyses, P< .05 was considered to be
statistically signiﬁcant.
3. Results
3.1. Baseline characteristics
Between 2006 and 2012, we prospectively recruited 984 CKD
patients from 11 centers. The baseline characteristics of the study
participants are presented in Table 1. Among a total of 984
patients, 56.1% were men, and the mean age was 49.7±15.8
years. A total of 267 participants (27.1%) had DM, and 527
(53.6%) had HTN. The mean eGFR level was 50.8±31.6mL/
min/1.73m2, the urinary protein-to-creatinine ratio (UPCR) was
2.2±2.6g/g creatinine, and the high-sensitivity C-reactive
protein (hs-CRP) level was 0.7±2.4mg/dL. The median cTNFR1
and cTNFR2 levels were 2703.4pg/mL (IQR 225.6–13,057.7pg/
mL) and 5661.0pg/mL (IQR 634.9–30,599.6pg/mL), respec-
tively. The group of patients in the highest tertile of ln cTNFRs
had higher percentages of older individuals, males, and DM
patients compared with those in the lowest tertile (Table 2). They
also had a higher serum hs-CRP level and more advanced CKD
based on both the lower eGFR and higher UPCR.
3.2. Associations of clinical parameters with cTNFR levels
Risk factors for CVD or CKD were studied by examining their
correlations with each other and with the ln cTNFR levels
(Table 3). A signiﬁcant negative correlation between the eGFR
and ln cTNFR2 level was observed (Pearson correlation
coefﬁcient [r]=0.67, P< .001 for ln cTNFR2). Age, SBP,
low-density lipoprotein (LDL), body mass index (BMI), protein-
uria (UPCR), and the hs-CRP level were positively correlated3
Table 3
Correlation coefﬁcients between various clinical parameters in CKD patients.
Ln cTNFR1 Age SBP eGFR LDL BMI UPCR hs-CRP
Ln cTNFR2 0.86
∗
0.43
∗
0.11† 0.67∗ 0.09† 0.14∗ 0.21∗ 0.10†
Ln cTNFR1 1.00 0.43
∗
0.17
∗ 0.75∗ 0.12† 0.16∗ 0.21∗ 0.06
Age 1.00 0.15
∗ 0.51∗ 0.15∗ 0.25∗ 0.15∗ 0.05
SBP 1.00 0.15∗ 0.08† 0.25∗ 0.19∗ 0.02
eGFR 1.00 0.01 0.19∗ 0.05 0.03
LDL 1.00 0.04 0.31
∗ 0.02
BMI 1.00 0.01 0.03
UPCR 1.00 0.04
hs-CRP 1.00
BMI = body mass index, eGFR = estimated glomerular ﬁltration rate, LDL = low-density lipoprotein, Ln cTNFR = log-transformed circulating tumor necrosis factor receptor, UPCR = urine protein-to-creatinine
ratio.
† P< .001.
∗
P< .0001.
Bae et al. Medicine (2017) 96:19 Medicinewith the ln cTNFR2 level (Table 3), but the degree of correlation
was less than that for the eGFR (r=0.43 for age, r=0.11 for SBP,
r=0.13 for BMI, r=0.21 for UPCR, and r=0.10 for hs-CRP; for
all P< .05). Similar results were observed for serum cTNFR1
except hs-CRP. There was no signiﬁcant correlation of the
cTNFR1 level with the hs-CRP level. To identify the relationship
between the cTNFRs andCVD,we divided the patients according
to CVD status. The median ln cTNFR1 and 2 levels were higher
in the patients with CVD than in those without CVD (ln cTNFR1:
positive CVD group vs. negative CVD group, 8.3 vs 7.7pg/mL, P
for trend<.001; cTNFR2: 9.0 vs 8.5pg/mL). In addition, more of
the participants with CVD were elderly, male and had advanced
CKD, diabetes than those without CVD (table S1, http://links.
lww.com/MD/B691).3.3. Prediction of CVD based on cTNFR levels
A total of 36 (3.7%) patients experienced CVD during
the median follow-up period of 3.4±2.0 years. The impact
of ln cTNFR expression on CVD was evaluated using
Kaplan–Meier analysis (Fig. 2). The results showed a signiﬁcant
difference between the ln cTNFR levels and that they were
associated with CVD. The CVD-free rate was signiﬁcantly
lower among the patients in the highest tertile of ln cTNFR1
(P< .001, log-rank test). A similar relationship was observed
for cTNFR2.A
Num
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cTNFR2 T1
cTNFR2 T2
cTNFR2 T3
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Figure 2. Circulating tumor necrosis factor receptors (cTNFRs) and event-free su
analysis and the log-rank test revealed a signiﬁcant difference in event-free surviv
4Based on the univariate Cox regression analysis results,
stepwise multivariate regression analysis was then performed to
examine the predictive potential of cTNFRs for CVD (Table 4).
The results of this analysis revealed that the ln cTNFR2 level
was an independent predictor of CVD in the CKD patients, even
after adjustments for age, sex, inﬂammation (hs-CRP), and CVD
risk factors, such as the BMI, SBP, DM, UPCR, eGFR, and LDL
(ln cTNFR2: hazard ratio [HR] 4.16, 95% CI 1.59–9.03,
P< .001). Similar result was observed for ln cTFNR1 level.
However, the strength of predictive value for CVD was lower
than that of ln TNFR2. Figure 3 shows the HRs for CVD
according to the spline ln TNFR2 level adjusted for CVD risk
factors. As the ln TNFR2 level increased, the HR for CVD
increased steeply.
To elucidate the potential of cTNFR2 to serve as a reliable
predictor of CVD, we conducted receiver operating characteristic
curve and NRI analyses (table S2, http://links.lww.com/MD/
B691). The incremental predictive values of hs-CRP and cTNFR2
for CVD showed improvement in discrimination according to the
c statistic, although this improvement was not statistically
signiﬁcant. After adjustments for traditional risk factors,
including age, sex, SBP, BMI, and DM, the inclusion of hs-
CRP and cTNFR2 increased the area under the curve (from 0.829
to 0.846; P= .134) for the prediction of CVD occurrence. The
NRI showed signiﬁcant improvement in discrimination (NRI=
534%, CI 19.2–87.5, P= .002).B
ber At Risk (n)
FR2 T1
FR2 T2
FR2 T3
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Table 4
Hazard ratios of ln circulating tumor necrosis factor receptors with clinical endpoints in CKD patients.
Ln cTNFR1 Ln cTNFR2
HR (95% CI) P HR (95% CI) P
CVD
Model 1
∗
3.477 (1.802–6.709) <.001 4.988 (2.553–9.744) <.001
Model 2† 3.066 (1.568–5.996) .001 4.540 (2.290–9.000) <.001
Model 3‡ 2.506 (1.186–5.295) .016 4.156 (1.913–9.030) <.001
All-cause mortality
Model 1
∗
2.161 (0.856–5.452) .103 8.138 (2.895–22.873) <.001
Model 2† 1.810 (0.710–4.612) .214 7.774 (2.757–21.923) <.001
Model 3‡ 0.870 (0.245–3.094) .830 7.448 (2.319–23.925) .001
ESRD
Model 1
∗
9.101 (6.764–12.246) <.001 6.832 (5.220–8.942) <.001
Model 2† 10.102 (7.137–14.298) <.001 6.378 (4.811–8.454) <.001
Model 3‡ 5.927 (3.412–10.296) <.001 3.297 (2.192–4.959) <.001
BMI = body mass index, CI = conﬁdence interval, eGFR = estimated glomerular ﬁltration rate, ESRD = end-stage renal disease, HR = hazard ratio, LDL = low-density lipoprotein, Ln cTNFR = log-transformed
circulating tumor necrosis factor receptor, UPCR = urine protein-to-creatinine ratio.
∗
Model 1 was adjusted for age and sex.
†Model 2 was adjusted for age, sex, and inﬂammation (hs-CRP).
‡Model 3 was adjusted for age, sex, inﬂammation (hs-CRP), and CVD risk factors (the BMI, SBP, DM, UPCR, eGFR, and LDL).
Bae et al. Medicine (2017) 96:19 www.md-journal.com3.4. Prediction of all-cause mortality and renal outcome
based on cTNFR levels
We also explored the impacts of the cTNFR levels on all-cause
mortality and ESRD as a secondary outcome (Table 4). ESRD
developed in 174 patients (17.7%), and 19 deaths (1.9%)
occurred during the follow-up period. The ln TNFR2 level at
baseline was signiﬁcantly predictive of not only all-cause
mortality (HR 7.45, 95% CI 2.32–23.93, P= .001) but also
ESRD (HR 3.30, 95% CI 2.19–4.96, P< .001). In contrast with
ln cTNFR2, the ln cTNFR1 level was not signiﬁcantly predictive
of all-cause mortality.Ln cTNFR2 (pg/ml) 
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Figure 3. Multivariate Cox proportional hazard ratio for cardiovascular disease
according to spline log-transformed circulating tumor necrosis factor receptor
2 (cTNFR2). The solid-black curve was obtained by multivariate Cox analysis
according to the spline log-transformed cTNFR2 (ln cTNFR2) level adjusted for
age, sex, systolic blood pressure, body mass index, and diabetes.
53.5. Subgroup analyses according to the baseline
characteristics
Next, we performed subgroup analysis to conﬁrm the predictive
value of cTNFR2 in the different subgroups. The association of
cTNFR2with CVD risk persisted in subgroup analyses according
to the categories of age, sex, proteinuria, the eGFR, and evidence
of DM, even after adjusting for the covariates. The cTNFR2 level
was found to be an independent predictor of CVD in all age (age
>65 years: HR 5.69; 95% CI 1.46–22.12, age <65 years: HR
3.37; 95% CI 1.11–10.24; P= .033), males (HR 5.37; 95% CI
1.93–14.95; P= .001), the lower proteinuria group (UPCR<3.5
g/gcr) (HR 2.64; 95% CI 1.08–6.42; P= .033), the lower eGFR
group (eGFR<30mL/min/1.73m2) (HR 3.96; 95% CI
1.44–10.91; P= .0008), and the DM group (HR 7.725; 95%
CI 2.28–23.08; P= .001) (Fig. 4). No signiﬁcant interactions were
detected among the subgroups except DM (for all interactions,
P> .05). We also performed subgroup analysis to conﬁrm the
predictive value of cTNFR1 in the different subgroups (age, sex,
proteinuria, the eGFR, and evidence of DM). However, there was
no signiﬁcant association between cTNFR1 and CVD in any
subgroup analysis (Supplementary Fig. 1, http://links.lww.com/
MD/B691).
4. Discussion
We found a strong association of cTNFRs with CVD risk in a
large, multicenter prospective CKD cohort. Furthermore, the
association of the cTNFR2 level at the time of initial diagnosis
remained signiﬁcant after adjusting for CVD risk factors and was
stronger in the participants whowere male or had advanced CKD
or DM.
Although associations between renal dysfunction and cTNFRs
have been described in the elderly,[15] diabetes patients,[13,14] and
individuals with glomerulonephritis,[16,19] there is a paucity of
data on the correlation between CVD and cTNFRs in CKD
patients. To our knowledge, the present study is the ﬁrst
prospective, multicenter study to report a relationship between
CVD and the cTNFR levels in these patients.
TNF-a is a functional, 26kDa, homotrimeric, transmembrane
protein and is a dualistic cytokine with proinﬂammatory and
[32,33] [43]
0.300
0.517
0.036
0.985
0.555
Interaction p-values
0.1 1 10 100
Age > 65 years
Age ≤ 65 years
Female
Male
Non-DM
DM
3.37 (1.11-10.24) 0.033
5.69 (1.46-22.12)        0.012
1.51 (0.33-6.84)          0.596
5.37 (1.93-14.95) 0.001
1.45 (0.44-4.77)      0.545
7.25 (2.28-23.08)    0.001
HR  (95% CI) P-values
UPCR ≥ 3.5 (g/g · cr)
UPCR < 3.5 (g/g · cr)
2.68 (0.49-14.81) 0.257
2.64 (1.08-6.42)        0.033
eGFR ≥ 30 (ml/min/1.73m2)
eGFR < 30 (ml/min/1.73m2)
1.93 (0.38-9.74) 0.427
3.96 (1.44-10.91)       0.008
Figure 4. Subgroup analysis of the risk of cardiovascular disease in chronic kidney disease patients with respect to log-transformed circulating tumor necrosis
factor receptor 2. The adjusted covariates included age, sex, high-sensitivity C-reactive protein, body mass index, systolic blood pressure, proteinuria, the
estimated glomerular ﬁltration rate, and diabetes.
Bae et al. Medicine (2017) 96:19 Medicineimmunoregulatory functions. Microinﬂammation driven
by TNF-a is directly involved in the pathogenesis and progression
of CKD. The TNF-a pathway activates cellular damage and
apoptosis, recruits inﬂammatory cells, and causes tubulointer-
stitial changes.[18,34] TNF-a increases albumin permeability, and
its inhibition in a diabetic animal model has been shown to
decrease albuminuria.[35] These functions are relayed by TNFRs,
which exist in soluble or membrane-bound forms,[36,37] and
cTNFR1 and cTNFR2 are expressed in glomerular and tubular
cells after renal injury.[34] In our study, elevated cTNFR levels
were implicated in the deterioration of renal function, along with
a decreased eGFR and increased proteinuria (UPCR) and ESRD.
In addition, elevated cTNFR levels, and particularly an
increase in cTNFR2, at the time of diagnosis was strongly
correlated with DM. These ﬁndings can be explained as follows.
First, TNF-a is a mediator of obesity-related insulin resistance,[38]
and the atherosclerotic process, which involves macrophages,
endothelial cells, and smoothmuscle cells,[39] but it is also derived
from adipose tissue.[40] Second, hyperglycemia has been
suggested to affect the levels of oxidative stress,[41] and oxidative
stress also increases TNF-a activity, and speciﬁcally the activity
of TNFR2.[42]
Previous studies have assessed the associations between
cTNFRs and left ventricular mass,[43] carotid atherosclerosis,[44]
coronary heart disease,[45,46] MI,[47] and HF.[48] In addition,
several experimental studies have demonstrated a role of
TNF signaling in myocardial cell apoptosis, leading to
ischemic reperfusion injury, left ventricular dysfunction, and
HF.[48,49] TNF-a plays an important role in cardiac toxicity
through reactive oxygen species and mitogen-activated protein
kinase pathways, as well as through interactions with
the renin–angiotensin system in experimental settings.[43,50,51]
Elevated cTNFR levels may also be reﬂective of inﬂammatory6mechanisms involved in subclinical atherosclerotic diseases. In
accordance with previous studies, cTNFR2 was found to be an
independent risk factor for CVD in our study and to be predictive
of CVD, especially in the participants with a lower proteinuria
level and advanced CKD and DM. These results can be explained
by 2 hypotheses. The ﬁrst hypothesis is that an elevated cTNFR2
level is a manifestation of the disease process, particularly in the
high-risk group, but not in the lower proteinuria group. The
second hypothesis is that an elevated cTNFR2 level contributes to
the development of CVD. Interestingly, in our study, cTNFR2
had a much more pronounced and signiﬁcant effect on CVD and
mortality than cTNFR1. This difference may be attributed to the
distinct natures of cTNFR1 and 2. Indeed, cTNFR1 is abundantly
expressed in all nucleated cells, but cTNFR2 expression is
restricted mainly to endothelial cells and leukocytes, although its
distribution varies between normal and diseased tissues.[52,53]
Each receptor may play a distinct role in inﬂammation and
apoptosis, but they also cooperate to regulate many of their
downstream effects.[20,54,55] The origins and roles of cTNFRs,
however, are still a matter of debate. Further pathogenic
studies of cTNFR2 with respect to inﬂammation and adverse
cardiac events are needed. In addition, this study evaluated
the incremental predictive values of cTNFRs for CVD, and
cTNFR2 showed improvement over traditional risk factors in
predicting CVD.
The strengths of our study were the large, multicenter,
prospective cohort, and the assessment of detailed participant
characteristics focusing on CVD risk factors. The limitation was
the lack of information on medications, long-term outcomes, and
cTNFR levels during the follow-up period. In addition, we only
analyzed the cTNFR levels at the time of enrollment; however,
our ﬁndings demonstrate that a single cTNFR measurement
provides information on the future risk of CVD. Further, we did
renal dysfunction: a prospective cohort study. Nephrology 2015;20:
Bae et al. Medicine (2017) 96:19 www.md-journal.comnot measure any other cardiac biomarkers, such as troponin and
natriuretic peptides, except for hs-CRP in this population. Thus,
we could not compare the predictive roles of cTNFRs with other
established predictors for CVD.
In conclusion, cTNFRs were shown to be associated with
CVD, independent of age, sex, inﬂammatory markers, and other
CVD risk factors, in the CKD patients. The predictive effect of
cTNFR2 was pronounced in the elderly (>65 years), male,
advanced CKD, and DM patients. Accordingly, this study may
provide a noninvasive method of CVD prediction and renal
function assessment in CKD patients. Further investigations are
needed to establish the use of cTNFRs as biomarkers for CVD
prediction in the CKD population.Acknowledgments
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